Koyfin Home > Directory > Health Care > Aimmune Therap > EBITDA

Aimmune Therap EBITDA Chart (AIMT)

Aimmune Therap annual/quarterly EBITDA from 2014 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Aimmune Therap EBITDA for the quarter ending June 06, 2020 was $-65m a 1.71% decrease of -1m year over year
  • Aimmune Therap EBITDA for the last 12 months ending June 06, 2020 was $-278m a 14.37% decrease of -40m year over year
  • Aimmune Therap Annual EBITDA for 2019 was $-246m a 13.01% decrease of -32m from 2018
  • Aimmune Therap Annual EBITDA for 2018 was $-214m a 38.10% decrease of -81m from 2017
  • Aimmune Therap Annual EBITDA for 2017 was $-132m a 38.78% decrease of -51m from 2016
Other Income Statement Metrics:
  • Aimmune Therap Net Income for the quarter ending December 12, 2018 was $-57m a 13.15% decrease of -7m year over year
View Chart On Koyfin

Quarterly AIMT EBITDA Data

06/2020$-65m
03/2020$-84m
12/2019$-66m
09/2019$-63m
06/2019$-62m
03/2019$-54m
12/2018$-58m
09/2018$-53m
06/2018$-53m
03/2018$-50m

Annual AIMT EBITDA Data

2019$-246m
2018$-214m
2017$-132m
2016$-81m
2015$-36m
2014$-11m
2013$-5m